Pfizer/Boehringer Spiriva For COPD Maintenance Therapy Approved By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Anticipating strong demand for the inhalation therapy, Pfizer and Boehringer are delaying launch until mid-year to ensure sufficient initial supplies of tiotropium bromide.
You may also be interested in...
Pfizer/Boehringer Ingelheim’s Spiriva Linked To Stroke In FDA MedWatch Alert
Pooled analyses of data on COPD treatment show increased risk of stroke in two patients per 1,000, agency says.
Pfizer/Boehringer Ingelheim’s Spiriva Linked To Stroke In FDA MedWatch Alert
Pooled analyses of data on COPD treatment show increased risk of stroke in two patients per 1,000, agency says.
Pfizer/Boehringer Spiriva Launched At 30% Discount To Advair For COPD
The average wholesale price for a 30-day supply of tiotropium is $115.20, versus $163.41 for fluticasone/salmeterol. Spiriva is now available nationwide, four months after approval.